Pharmaceutical Business Review

AUGUST 14, 2024

The vaccine candidate is a virus-like particle (VLP)-based, adjuvanted vaccine designed for active immunisation against chikungunya virus (CHIKV) infection. The US regulator will make a decision on the vaccine approval under the Prescription Drug User Fee Act (PDUFA) by 14 February 2025.

Vaccines 105

Vaccines 105

pharmaphorum

FEBRUARY 1, 2021

The diplomatic row that broke out last week over the supply of AstraZeneca’s vaccine to Europe appears to have cooled after the UK pharma agreed to supply an extra nine million doses. Step forward on vaccines. The post AstraZeneca to supply nine million more vaccines to EU appeared first on.

Vaccines 115

Vaccines 115

Pharmaceutical Business Review

SEPTEMBER 6, 2024

This recommendation will aid in the potential authorisation of the vaccine for use in individuals aged six months and older to prevent Covid-19 in the upcoming 2024-2025 autumn/winter season. 1 family of Omicron subvariants for the upcoming vaccination campaign. Moderna’s vaccine targeting the JN.1

Vaccines 104

Vaccines 104

European Pharmaceutical Review

OCTOBER 6, 2023

Positive interim results from Moderna’s Phase I/II trial of mRNA-1083 , an investigational vaccine designed to immunise against both influenza and COVID-19, have been released. There are several benefits of the combination vaccine as a preventative measure against these respiratory conditions, according to the pharmaceutical company.

Vaccines 105

Vaccines Pharmaceutical Companies Pharmaceutical Companies 105

pharmaphorum

MARCH 14, 2025

The FDA has released its recommendations on the composition of influenza vaccines for the 2025-26 season, without the input of its external advisors

Vaccines 80

Vaccines 80

Express Pharma

OCTOBER 25, 2023

With influenza season well underway, vaccination campaigns are in full force in the northern hemisphere. This will reshape the global influenza vaccine market for the upcoming seasons, says GlobalData. Kurdach continues, “When the actual composition of vaccines will revert to trivalent formulations remains another question.

Vaccines 98

Vaccines 98

pharmaphorum

FEBRUARY 17, 2025

GSK joins arch-rival Pfizer in the market for five-in-one meningococcal vaccines with FDA approval for Penmenvy, a top launch prospect for 2025.

Vaccines 75

Vaccines 75

European Pharmaceutical Review

SEPTEMBER 28, 2023

There has been a steady stream of developments in the vaccine manufacturing space throughout 2023. A notable milestone was Moderna’s announcement in April that it had, following finalisation of a ten-year strategic partnership with the UK Government, commenced construction of its mRNA vaccine manufacturing technology centre.

Vaccines 98

Vaccines Pharmaceutical Manufacturing 98

European Pharmaceutical Review

MARCH 6, 2023

” Post-construction, the facility “will harness mRNA science that aims to develop and deliver innovative vaccines to the UK public that address emerging threats from respiratory viruses.” The Moderna Innovation and Technology Centre is expected to become operational in 2025.

Vaccines 98

Vaccines 98

Express Pharma

JUNE 3, 2024

mRESVIA is Moderna’s second approved product and reportedly the only RSV vaccine available in single-dose pre-filled syringes Moderna, announced that the U.S. This approval is also the first time an mRNA vaccine has been approved for a disease other than COVID-19. The primary analysis with 3.7 per cent (95.88 per cent CI 66.0

Vaccines 81

Vaccines Adverse Reactions Packaging 81

Pharmacy Times

APRIL 2, 2025

The only major change is in the included strain of influenza A/H2N2 virus, which has been updated for both the egg-based and the cell- and recombinant-based vaccines.

Vaccines 49

Vaccines 49

pharmaphorum

SEPTEMBER 15, 2020

billion) order for up to 190 million doses of a coronavirus vaccine in development at French company Valneva. The new deal firms up an earlier agreement in principle with the UK in July that covered up to 100 million doses of VLA2001 , a purified inactivated SARS-CoV-2 vaccine that is expected to require a two-dose vaccination regimen.

Vaccines 80

Vaccines Immunity Immunization 80

Pharma Marketing Network

APRIL 13, 2025

In this article, well unpack the most effective SEO marketing strategies that align with pharma brands and the 2025 shifting strategyhelping you drive organic traffic while remaining compliant and trusted. H3: Use Persona-Based SEO Research In 2025, audience segmentation is evolving with AI-driven persona modeling.

Diabetes 52

Diabetes Dosage Vaccines 52

Big Molecule Watch

SEPTEMBER 3, 2024

On August 22, Moderna announced that FDA approved its supplemental Biologics License Application (“sBLA”) for a new formula of their COVID-19 vaccine, SPIKEVAX®, for individuals 12 years old and above. Emergency Use Authorization (“EUA”) was also granted for the updated vaccine for individuals aged 6 months to 11 years old.

Vaccines 59

Vaccines Hospitals 59

Pharmaceutical Business Review

SEPTEMBER 2, 2024

The Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) [NVX-CoV2705] is now authorised for active immunisation against Covid-19. Following the EUA, the vaccine is also recommended by the US Centers for Disease Control and Prevention (CDC). Our updated vaccine targets JN.1, 1.” “Our updated vaccine targets JN.1,

Vaccines 59

Vaccines Adverse Reactions Immunity Immunization 59

Pharmaceutical Business Review

AUGUST 9, 2024

Additionally, the contract includes around $17m for additional services from 2025 to 2027, which encompasses the storage of vaccine doses within the US. The vaccine, known as MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic, is marketed under various brand names, JYNNEOS, IMVANEX, and IMVAMUNE.

Vaccines 59

Vaccines 59

Pharmacy Times

MARCH 23, 2025

Goad, PharmD, MPH, discusses the latest RSV vaccination guidelines and recommendations for 2025, highlighting vaccine options, target populations, timing considerations, evolving CDC policies, and the role of pharmacists in immunization efforts.

Vaccines 29

Vaccines Immunity Immunization 29

Pharmaceutical Technology

SEPTEMBER 12, 2024

The vaccine manufacturer said it could also supply 13 million doses by YE 2025 to meet requests by Africa CDC and UNICEF.

Vaccines 52

Vaccines 52

Express Pharma

MARCH 3, 2025

Zydus Lifesciences announced its focus on the development of a combination vaccine against shigellosis and typhoid. Zydus will carry out early-stage development, animal immunogenicity studies and regulatory preclinical toxicology studies for this combination vaccine.

Vaccines 52

Vaccines Immunity Immunization 52

Big Molecule Watch

FEBRUARY 17, 2025

On February 5, 2025 Valneva SE (Valneva) announced that the United Kingdoms Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorization for Valnevas chikungunya vaccine, IXCHIQ. The post UKs MHRA Grants Marketing Authorization for Chikungunya Vaccine appeared first on Big Molecule Watch.

Vaccines 45

Vaccines Immunization Immunity Labelling 45

Pharmaceutical Technology

APRIL 25, 2023

As the prophylactic landscape for malaria has changed in recent years with vaccine approvals, major issues still remain with ensuring access in remote communities. However, making sure the vaccine reaches everyone can be challenging due to the storage requirements. The Mosquirix vaccine contains two vials.

Vaccines 69

Vaccines Communication Pharmaceutical Companies Pharmaceutical Companies 69

Big Molecule Watch

SEPTEMBER 17, 2024

On September 13, 2024, the World Health Organization (WHO) announced that it added the first vaccine against monkeypox (mpox) to its prequalification list. The vaccine, MVA-BN, is manufactured by Bavarian Nordic A/S. Prequalification is a mechanism “used to evaluate quality, safety and efficacy of medical products, such as vaccines.

Vaccines 49

Vaccines Labelling 49

Pharmaceutical Technology

DECEMBER 6, 2022

Evaxion Biotech and ExpreS 2 ion Biotechnologies have entered a vaccine discovery collaboration agreement to co-develop a new cytomegalovirus (CMV) vaccine candidate. Until 2025, the companies will equally share the research and intellectual property licensing expenses under the partnership.

Vaccines 52

Vaccines Immunity Immunization 52

Pharmacy Times

SEPTEMBER 2, 2024

Robert Walker discusses the updated COVID-19 vaccines targeting the new JN.1 1 lineage of the virus and the challenges of addressing vaccine hesitancy to protect individuals and communities.

Vaccines 36

Vaccines 36

Pharmacy Times

JULY 23, 2024

With new guidance coming for the 2024-2025 season, pharmacists must stay up to date with current vaccine recommendations.

Vaccines 37

Vaccines 37

Pharmacy Times

APRIL 16, 2024

The 5-in-1 meningococcal ABCWY vaccine candidate has an assigned Prescription Drug User Fee Act action date of February 14, 2025.

Vaccines 37

Vaccines 37

Pharmaceutical Technology

JANUARY 30, 2023

According to GlobalData’s Drugs database, there were 22 prophylactic vaccines in development for COVID-19 with sales forecasts available in H2 2022. Of these 22 vaccines, mRNA-derived vaccines dominate, with Comirnaty and Moderna’s Spikvax accounting for 88% of 2022 sales, with 58% and 30%, respectively.

Vaccines 52

Vaccines 52

Pharmacy Times

JANUARY 27, 2025

Approximately 66% of patients received a COVID-19 vaccine in the fall of 2024 and only 26% received a respiratory syncytial virus vaccine.

Vaccines 33

Vaccines 33

Pharmacy Times

MARCH 22, 2025

Pharmacists can empower patient RSV vaccination through strategic communication and personalized care.

Vaccines 20

Vaccines Communication 20

Express Pharma

DECEMBER 20, 2024

Renowned for its extensive production of generic drugs and vaccines, the sector has played a pivotal role in addressing global healthcare demands. As of 2024, India has produced nearly half of the eight billion vaccine doses distributed worldwide, cementing its reputation as a reliable healthcare contributor.

Biosimilars 103

Biosimilars Vaccines 103

Express Pharma

AUGUST 22, 2024

The US Food and Drug Administration approved and granted emergency use authorisation (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent (single) component that corresponds to the Omicron variant KP.2 Today’s actions relate to updated mRNA COVID-19 vaccines manufactured by ModernaTX and Pfizer.

Vaccines 105

Vaccines 105

STAT

JUNE 10, 2024

… Moderna announced that, in a Phase 3 clinical trial, its combination Covid-19 and influenza vaccine generated stronger immune responses in older adults than individual vaccines targeting those viruses , STAT says. A combo shot could improve uptake of both flu and Covid vaccines.

Vaccines 244

Vaccines Immunity Immunization 244

Express Pharma

FEBRUARY 20, 2025

CDMO Live is set to take place on 7-8 May 2025 at Rotterdam’s World Trade Center, bringing together key decision-makers in pharmaceutical outsourcing. The 2025 edition will feature talks from senior executives at companies including Johnson & Johnson, AstraZeneca, Bristol Myers Squibb, UCB, Bayer, Valneva, Polpharma, and MSD.

Pharmaceutical Manufacturing 101

Pharmaceutical Manufacturing Vaccines Pharmaceutical Companies Pharmaceutical Companies 101

Express Pharma

JUNE 26, 2024

The success of the COVID-19 mRNA vaccines highlighted the major advantages of utilising mRNA technology in vaccine development. Consequently, the FDA has awarded a rising number of review designations to mRNA vaccines in recent years. Implementation of these vaccines is estimated to have prevented 14.4

Vaccines 111

Vaccines Immunity Immunization 111

Express Pharma

JANUARY 22, 2024

Cameroon has kickstarted the world’s first routine vaccine programme against malaria. It is one of 20 African countries planning to introduce the drug this year, according to global vaccine alliance Gavi. The vaccine is designed to be administered to young children in four doses from around five months of age.

Vaccines 105

Vaccines 105

pharmaphorum

DECEMBER 22, 2022

Construction will start early next year of a new manufacturing centre in the UK with the capacity to produce 250 million vaccine doses per year, the centrepiece of a 10-year alliance between the government and US biotech Moderna. The first vaccines are due to be produced at the new facility in 2025.

Vaccines 122

Vaccines 122

European Pharmaceutical Review

MARCH 4, 2025

Four medicines were recommended for approval at the EMAs human medicines committee (CHMP)s February 2025 meeting. Following its approval by the FDA in 2023, the CHMP has recommended extending the existing indication of the chikungunya vaccine Ixchiq (chikungunya vaccine (live)) , to individuals from 12 years old.

Vaccines 94

Vaccines 94